

PATENT APPLICATION NO.: 10/083,357
ATTORNEY DOCKET NO.: TECH02-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1636

Handwritten initials

Applicants: Zeng et al.

Application No.: 10/083,357

Group Art Unit: 1636

Filed: May 17, 2002

Examiner:

Title: Systematic discovery of new genes and genes discovered thereby

RECEIVED

APR 09 2003

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>4/03/03</u>	<u><i>Obert Chu</i></u>
Date	Signature
<u>Obert Chu</u>	
Typed or printed name of person signing certificate	

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)

☐ under 37 CFR 1.97(c) together with either:
☐ a Statement under 37 CFR 1.97(e), as checked below, or
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:
☐ a Statement under 37 CFR 1.97(e), as checked below, and
☐ a Petition under 37 CFR 1.97(d)(2), and
☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☐ Applicant requests that the attached IDS and cited reference(s) _____ be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

- ☒ Copies of the cited references are enclosed, except for United States Patents.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Serial No. _____, and references that are not required to be submitted under 37 CFR 1.98.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

Concise Explanation Requirement (non-English references):

- ☐ The "concise explanation" requirement for reference(s) _____ under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.


It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ Enclosed is a check in the amount of \$_____.
- ☐ Please charge Deposit Account 501040 in the amount of \$_____.
- ☐ A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 501040.

Respectfully submitted,

GENOME THERAPEUTICS CORPORATION

By 
Nina L. Pearlmutter, Ph.D., Esq.
Registration No.: 35,639
Telephone: (781) 398-2300
Facsimile: (781) 398-2607

Waltham, Massachusetts 02453

Dated: 4/2/03

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
TECH02-02APPLICATION NO.
10/083,357INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT
Zeng, Qiandong et al.FILING DATE
May 17, 2002GROUP
1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,966,712	Oct. 12, 1999	Sabatini et al.	707/ 104	707/ 10 435/6	
	AB	6,033,861	March 7, 2000	Schafer et al.	435/6	435/ 91.1 536/ 24.1	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 00/15782 A1	Mar. 23, 2000	WO			
	AM						
	AN						
	AO						
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Andrade et al. (1997). "Characterization of New Proteins found by analysis of short Open Reading Frames from the full yeast genome." <i>Yeast</i> . 13:1363-1374
AS	Cliften et al. (2001). "Surveying <i>Saccharomyces</i> genomes to identify functional elements by comparative DNA sequence analysis." <i>Genome Research</i> . 11:1175-1186
AT	Miyajima et al. (2000). "Computational and experimental analysis identifies many novel human genes." <i>Biochemical and biophysical research communications</i> . 272:801-807

EXAMINER

DATE CONSIDERED